Nyxoah SA has achieved a significant legal victory with a default ruling from the Unified Patent Court in Munich, Germany, against Inspire Medical Systems. This ruling is a crucial development for Nyxoah as it continues to navigate the competitive landscape of medical technology, particularly in the treatment of Obstructive Sleep Apnea (OSA).
On November 18, 2026, Nyxoah announced that the court had decided in its favor regarding a patent infringement case involving its European Patent 2 760 534. The company had initiated the case against Inspire Medical Systems, asserting that the latter infringed on its intellectual property.
Nyxoah is now considering various enforcement options following this ruling, which could have significant implications for its business strategy and competitive positioning. The company specializes in innovative solutions for OSA, and this legal victory may enhance its ability to protect its technologies and market share.
Background
Nyxoah SA, incorporated in Belgium, operates in the surgical and medical instruments and apparatus sector (SIC 3841). The company is publicly traded on both Euronext Brussels and Nasdaq under the ticker symbol NYXH. Nyxoah focuses on developing treatment alternatives for OSA through neuromodulation, with its flagship product being the Genio system, a leadless and battery-free hypoglossal neurostimulation therapy.
In recent filings, Nyxoah has reported various developments, including successful clinical studies and regulatory approvals. The company completed its IPOs in September 2020 and July 2021, further establishing its presence in the medical technology market.
What the Filing Says
The filing indicates that Nyxoah received a favorable decision from the court, stating, "Nyxoah had filed an infringement case against Inspire Medical Systems at the UPC regarding Nyxoah’s European Patent 2 760 534." The company is now evaluating its options for enforcement.
Impact
This ruling may significantly affect Nyxoah's competitive landscape, particularly in relation to Inspire Medical Systems and other companies within the surgical and medical instruments sector. With this legal victory, Nyxoah could strengthen its market position and enhance its ability to protect its innovations against potential infringements.
What's Next
The filing does not specify what actions Nyxoah will take next in light of the ruling. However, the company has expressed its intention to explore enforcement options, which may lead to further developments in its ongoing legal strategy.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










